ACXP vs LPSN vs PRAX vs NICE

For growth investors, NICE Ltd.

(NICE) is the stronger pick with 7. 7% revenue growth year-over-year, versus -100. 0% for Praxis Precision Medicines, Inc. (PRAX). NICE Ltd. (NICE) offers the better valuation at 9. 9x trailing P/E (8. 7x forward), making it the more compelling value choice. Analysts rate Praxis Precision Medicines, Inc. (PRAX) a "Buy" — based on 16 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Praxis Precision Medicines, Inc.

(PRAX) delivered a total return of -20. 8%, compared to -99. 7% for LivePerson, Inc. (LPSN). Over 10 years, the gap is even starker: NICE returned +50. 7% versus ACXP's -98. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), NICE Ltd.

(NICE) is the lower-risk stock at 0. 72β versus Acurx Pharmaceuticals, Inc. 's 2. 42β — meaning ACXP is approximately 234% more volatile than NICE relative to the S&P 500. On balance sheet safety, Praxis Precision Medicines, Inc. (PRAX) carries a lower debt/equity ratio of 0% versus 4% for NICE Ltd. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), NICE Ltd.

(NICE) is pulling ahead at 7. 7% versus -100. 0% for Praxis Precision Medicines, Inc. (PRAX). On earnings-per-share growth, the picture is similar: Acurx Pharmaceuticals, Inc. grew EPS 69. 8% year-over-year, compared to -32. 0% for Praxis Precision Medicines, Inc.. Over a 3-year CAGR, NICE leads at 10. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

NICE Ltd.

(NICE) is the more profitable company, earning 20. 8% net margin versus -27. 6% for LivePerson, Inc. — meaning it keeps 20. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NICE leads at 21. 9% versus -9. 6% for LPSN. At the gross margin level — before operating expenses — NICE leads at 66. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for PRAX: 63.

3% to $544. 40.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, NICE Ltd.

(NICE) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 72)). Acurx Pharmaceuticals, Inc. (ACXP) carries a higher beta of 2. 42 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (NICE: +50. 7%, ACXP: -98. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (ACXP (Healthcare) and LPSN (Technology) and PRAX (Healthcare) and NICE (Technology)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: ACXP is a small-cap quality compounder stock; LPSN is a small-cap quality compounder stock; PRAX is a small-cap quality compounder stock; NICE is a small-cap deep-value stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.